Literature DB >> 19197791

Current developments in anti-HIV/AIDS gene therapy.

Alexander Y Tsygankov1.   

Abstract

Since the introduction of highly active retroviral therapy (HAART) in 1996, dramatic improvements in therapeutic treatment modalities for HIV type 1 (HIV-1) infection have occurred. Potent drug combinations in HAART regimens efficiently block HIV-1 replication in most patients; however, multiple shortcomings of HAART are apparent and require novel treatments that can be utilized in combination with HAART or as stand-alone therapies. Gene therapy of HIV-1 represents one such treatment and several strategies are currently under development. This review focuses on advancements in the gene therapy of HIV/AIDS by highlighting the progress made in selecting new therapeutic targets and developing novel tools to exert an effect on these targets. In addition, new trends emerging from this progress are summarized. This review is based primarily on literature published between 2006 and 2008.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19197791

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  6 in total

Review 1.  Targeting frameshifting in the human immunodeficiency virus.

Authors:  Léa Brakier-Gingras; Johanie Charbonneau; Samuel E Butcher
Journal:  Expert Opin Ther Targets       Date:  2012-03       Impact factor: 6.902

Review 2.  Current progress in the development of RNAi-based therapeutics for HIV-1.

Authors:  J Zhou; J J Rossi
Journal:  Gene Ther       Date:  2011-09-29       Impact factor: 5.250

Review 3.  Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.

Authors:  Jiehua Zhou; John J Rossi
Journal:  BioDrugs       Date:  2012-12-01       Impact factor: 5.807

4.  siRNA against KIR3DL1 as a potential gene therapeutic agent in controlling HIV-1 infection.

Authors:  Geng-Feng Fu; Ji-Cheng Pan; Nan Lin; Hai-Yang Hu; Wei-Ming Tang; Jin-Shui Xu; Xiao-Liang Wang; Xiao-Qin Xu; Tao Qiu; Xiao-Yan Liu; Guo-Hong Chen; Tanmay Mahapatra; Xi-Ping Huan; Hai-Tao Yang
Journal:  Viral Immunol       Date:  2014-05-16       Impact factor: 2.257

5.  Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge.

Authors:  Jiehua Zhou; C Preston Neff; Piotr Swiderski; Haitang Li; David D Smith; Tawfik Aboellail; Leila Remling-Mulder; Ramesh Akkina; John J Rossi
Journal:  Mol Ther       Date:  2012-11-20       Impact factor: 11.454

6.  Digoxin suppresses HIV-1 replication by altering viral RNA processing.

Authors:  Raymond W Wong; Ahalya Balachandran; Mario A Ostrowski; Alan Cochrane
Journal:  PLoS Pathog       Date:  2013-03-28       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.